Recognizing and correcting failures in glioblastoma treatment

Ashish H. Shah, Regina Graham, Amade Bregy, Michael Thambuswamy, Ricardo J. Komotar

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


While current treatment remains universal for glioblastoma, recent evidence has demonstrated marked heterogeneity in their molecular profiles. Due to the near universal rate of recurrence, attention has focused on individualized treatment and subgroup population differences that may influence the efficacy of adjuvant therapy. Recent studies have implicated chemo-radioresistant GBM stem cells (GSCs) in the propagation of heterogeneous tumor profiles. As a result, there has been a shift to classify and target GSCs in order to increase survival and delay relapse. The overall objective of our editorial is to highlight current failures in GBM treatment and to propose novel personalized methods to correct our shortcomings in GBM treatment.

Original languageEnglish (US)
Pages (from-to)299-302
Number of pages4
JournalCancer Investigation
Issue number6
StatePublished - Jul 2014


  • Editorial
  • Glioblastoma
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Recognizing and correcting failures in glioblastoma treatment'. Together they form a unique fingerprint.

Cite this